Investigation of setmelanotide, an MC4R agonist, for obesity in individuals with Smith-Magenis syndrome

This publication has 16 references indexed in Scilit:

• Excess body weight: Novel insights into its roles in obesity comorbidities
  Seminars in Cancer Biology, 2023
• Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period
  The Lancet Diabetes & Endocrinology, 2022
• Possible underreporting of pathogenic variants in RAI1 causing Smith–Magenis syndrome
  American Journal of Medical Genetics Part A, 2021
• A method for calculating BMI z-scores and percentiles above the 95^th percentile of the CDC growth charts
  Annals of Human Biology, 2020
• MC4R agonism promotes durable weight loss in patients with leptin receptor deficiency
  Nature Medicine, 2018
• Proopiomelanocortin Deficiency Treated with a Melanocortin-4 Receptor Agonist
  New England Journal of Medicine, 2016
• Rai1 haploinsufficiency causes reduced Bdnf expression resulting in hyperphagia, obesity and altered fat distribution in mice and humans with no evidence of metabolic syndrome
  Human Molecular Genetics, 2010
• Brain-Derived Neurotrophic Factor and Obesity in the WAGR Syndrome
  New England Journal of Medicine, 2008
• Brain-derived neurotrophic factor regulates energy balance downstream of melanocortin-4 receptor
  Nature Neuroscience, 2003
• Mutations in RAI1 associated with Smith–Magenis syndrome
  Nature Genetics, 2003